Interactions of the male contraceptive target EPPIN with semenogelin-1 and small organic ligands
- PMID:37658081
- PMCID: PMC10474283
- DOI: 10.1038/s41598-023-41365-1
Interactions of the male contraceptive target EPPIN with semenogelin-1 and small organic ligands
Abstract
Novel male contraceptives will promote gender equality in sharing contraceptive responsibility. The sperm-associated protein epididymal protease inhibitor (EPPIN) is a promising target for non-hormonal male contraception. EPPIN interacts with the semen coagulum protein semenogelin-1 (SEMG1) on the sperm surface, leading to transient inhibition of sperm motility after ejaculation. Small organic molecules targeting EPPIN's SEMG1-binding are under development as male contraceptives. Here, we combined computational approaches to uncover key aspects underlying EPPIN binding to SEMG1 and small organic ligands. We generated a human EPPIN model showing a typical arrangement of the WFDC (Whey-acid four disulfide core)-type and Kunitz-type domains, connected by a hinge region. Determining the EPPIN model's intrinsic motion by molecular dynamics simulations and normal mode analysis revealed a conformation, presenting a binding pocket that accommodates SEMG1Glu229-Gln247, EP055, and EP012. EPPIN's residues Phe63 and Lys68 (WFDC domain), Asp71 (hinge region), and Asn113, Asn114, and Asn115 (Kunitz domain) were identified as hot spots for SEMG1, EP055, and EP012 binding. Moreover, hydrophobic and hydrophilic residues in the WFDC and Kunitz domains allow plasma membrane anchoring, orienting the EPPIN binding pocket to the solvent. Targeting EPPIN's essential residues for its biomolecular interactions may improve the rational design of EPPIN ligands as spermiostatic compounds.
© 2023. Springer Nature Limited.
Conflict of interest statement
Michael G. O'Rand has stock ownership in Eppin Pharma Inc. Dr. O'Rand receives no salary from Eppin Pharma. He is retired from the University but retains his association with UNC and the Department of Cell Biology & Physiology. Katherine G. Hamil has stock ownership in Eppin Pharma Inc. She is a full-time employee of Eppin Pharma. This does not alter our adherence to policies on sharing data and materials. There are no restrictions on sharing our data. The other authors declare no competing interests.
Figures





References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
